Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

Subcutaneous Herceptin Receives FDA Approval for HER2-Positive Breast Cancer Treatment

Subcutaneous Herceptin Receives FDA Approval for HER2-Positive Breast Cancer Treatment

On 28 February, the United States Food and Drug Administration (FDA), for HER2-positive early-stage breast cancer in certain patients, together with chemotherapy, approved the subcutaneous (under-the-skin) form of trastuzumab, trastuzumab / hyluronidase-oysk (Herceptin Hylecta) , a smart drug. Eligible patients were defined as node-positive, or node-negative and hormone-negative, or having one high-risk factor. The FDA also approved it for HER2-positive metastatic breast cancer in patients previously receiving one or more lines of chemotherapy for metastatic disease, with paclitaxel or alone as trastuzumab / hyluronidase-oysk.

This new drug contains the same monoclonal antibody as conventional trastuzumab, but is formulated with recombinant human hyaluronidase PH20 to permit subcutaneous administration. Conventional trastuzumab (Herceptin) is given by intravenous (into a vein) infusion over 30-90 minutes, while trastuzumab / hyaluronidase-osk comes as ready-to-use syringes administered subcutaneously in 2-5 minutes.

Studies Leading to FDA Approval of Subcutaneous Trastuzumab: HannaH, SafeHER, and PrefHER

FDA approval for early-stage HER2-positive breast cancer was obtained from the results of 3 clinical trials:

  • In the phase III HannaH study, chemotherapy plus neoadjuvant and adjuvant trastuzumab / hyaluronidase oysk was compared with intravenous trastuzumab. Subcutaneous trastuzumab and hyaluronidase-oysk achieved blood levels equivalent to intravenous trastuzumab, with similar clinical efficacy results. The pathological complete response rate was % 45.4 with trastuzumab / hyaluronidase oysk and % 40.7 with trastuzumab alone.
  • The phase III SafeHER study of adjuvant trastuzumab / hyaluronidase-oysk was consistent with the known safety profiles and tolerability data for intravenous trastuzumab and trastuzumab / hyaluronidase-oysk.
  • PrefHER tested patients’ administration preferences and found that most (% 86) preferred trastuzumab / hyaluronidase oysk to intravenous trastuzumab.

In people receiving trastuzumab / hyaluronidase oysk for early breast cancer, the most common adverse effects were fatigue, joint pain, diarrhea, injection-site reaction, upper respiratory tract infection, rash, muscle pain, nausea, headache, swelling, flushing, fever, cough, and extremity pain.

Sources

FDA approves new formulation of Herceptin for subcutaneous use.
fda.gov - 28 February 2019

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

Subcutaneous Herceptin Receives FDA Approval for HER2-Positive Breast Cancer Treatment

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy